Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

141.10 2.33 +1.68%
Market cap
$9.6B
P/E
26.4×
Fwd P/E
24.7×
Dividend yield
—
F-score
6/9
Altman Z
9.09
Beneish M
−2.59
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
28.46 48.80 81.21 88.21

+8 more quarters

P/S ratio
3.46 5.06 7.38 8.61
P/FCF ratio
39.72 37.87 57.15 53.31
P/Operating CF
119.35 129.05 109.09 172.83
P/B ratio
7.42 11.27 13.20 15.69
EV/Sales
3.59 5.22 7.47 8.72
EV/EBITDA
17.83 25.17 35.85 41.91
EV/FCF
41.28 39.08 57.81 53.94
Current Ratio
2.48 2.49 2.81 2.87
Net Debt/EBITDA
2.64 3.15 1.37 1.84
Debt/Equity
0.67 0.73 0.63 0.73
Earnings Yield
3.51% 2.05% 1.23% 1.13%
Free Cash Flow Yield
2.52% 2.64% 1.75% 1.88%
Free Cash Flow per Share
0.74 1.23 0.48 1.34
Book value per Share
20.52 18.61 21.54 19.67
Free Cash Flow
51.10 86.00 33.90 94.60
EV/EBIT
21.26 29.88 42.69 50.30
Other line items

Show all line items

Columns are period end dates